Neurocrine Biosciences Inc. (NBIX)

HEALTH CARE: PHARMACEUTICALS
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

12780 EL CAMINO REAL SAN DIEGO, CA 92130

Neurocrine Biosciences Inc discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine-related diseases and disorders. The company's lead clinical development program, indiplon, is a drug for the treatment of insomnia.

Data as of 2020-11-22
Market Cap8.315 Billion Shares Outstanding93.429 Million Avg 30-day Volume958.373 Thousand
P/E Ratio94.7 Dividend Yield EPS0.94
Price/Sales7.98 Price cash flow ratio36.0 Price free cash flow ratio35.7
Book Value8.61 Price to Tangible Book10.34 Alpha0.01
Short Interest Ratio % Short Interest to Float R-squared0.149326
BETA1.13664 52-week High/Low136.265 / 72.14 Stddev0.123953
View SEC Filings from NBIX instead.
Q3 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 6 8 -25.0% 4 (0.26%) 5 (0.32%) -20.0%
Funds Holding: 397 408 -2.7% 118 (7.76%) 107 (6.94%) 10.28%
13F shares: 88.621 Million 90.366 Million -1.93% 17.859 Million 17.647 Million 1.2%
% Ownership 95.0306 96.9021 -1.93% 19.151 18.9237 1.2%
New Positions: 63 86 -26.74% 27 20 35.0%
Increased Positions 184 169 8.88% 49 39 25.64%
Closed Positions 67 36 86.11% 16 12 33.33%
Reduced Positions 106 109 -2.75% 33 41 -19.51%
Total Calls 400.112 Thousand 647.493 Thousand -38.21% 149.4 Thousand 184.7 Thousand -19.11%
Total Puts 1.366 Million 655.56 Thousand 108.42% 379.8 Thousand 115.4 Thousand 229.12%
PUT/CALL Ratio 3.41 1.01 237.62% 2.54 0.62 309.68%
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding NBIX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding NBIX BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

44.3 Thousand total shares from 11 transactions

Exercise Derivative Conversion (M)

20.6 Thousand total shares from 1 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

GORMAN KEVIN CHARLES CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
441,071 2020-11-12 5

BOZIGIAN HAIG P. CHIEF DEVELOPMENT OFFICER

  • Officer
152,694 2020-11-12 6

GRIGORIADIS DIMITRI E. CHIEF RESEARCH OFFICER

  • Officer
81,624 2020-11-12 8

GANO KYLE CHIEF BUSINESS DEVELOPMENT OFF

  • Officer
98,028 2020-11-12 5

LLOYD-SMITH MALCOLM CHIEF REGULATORY OFFICER

  • Officer
29,002 2020-11-12 5

LIPPOLDT DARIN CHIEF LEGAL OFFICER

  • Officer
30,082 2020-11-12 8

BENEVICH ERIC CHIEF COMMERCIAL OFFICER

  • Officer
17,405 2020-11-12 7

ABERNETHY MATT CHIEF FINANCIAL OFFICER

  • Officer
10,014 2020-11-12 7

ROBERTS EIRY CHIEF MEDICAL OFFICER

  • Officer
13,477 2020-11-12 7

COOKE JULIE CHIEF HUMAN RESOURCES OFFICER

  • Officer
11,580 2020-11-12 6

RASTETTER WILLIAM H

  • Director
0 2020-05-19 1

SHERWIN STEPHEN A

  • Director
0 2020-05-19 2

POPS RICHARD F

  • Director
0 2020-05-19 1

LYONS GARY A

  • Director
0 2020-05-19 1

MORROW GEORGE J

  • Director
0 2020-05-19 1

NORWALK LESLIE V

  • Director
0 2020-05-19 1

SHARP SHALINI

  • Director
0 2020-02-01 2

SANDROCK ALFRED

  • Director
0 2019-05-22 0

NEVINNY CORINNE H

  • Director
0 2018-05-24 0

OBRIEN CHRISTOPHER FLINT FORMER CHIEF MEDICAL OFFICER

  • Officer
55,946 2018-02-05 0

MOLLICA JOSEPH A

  • Director
0 2017-05-22 0

COUGHLIN TIMOTHY P CHIEF FINANCIAL OFFICER

  • Officer
137,961 2017-02-06 0

GROS DAVID-ALEXANDRE C PRESIDENT & COO

  • Officer
0 2017-02-06 0

MITCHELL W THOMAS

  • Director
1,000 2015-06-23 0

NEUROCRINE BIOSCIENCES INC

  • Director
16,030 2015-04-07 0

BVF PARTNERS L P/IL

BIOTECHNOLOGY VALUE FUND L P

BIOTECHNOLOGY VALUE FUND II LP

BVF INVESTMENTS LLC

BVF INC/IL

LAMPERT MARK N

  • SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
No longer subject to file 2012-02-09 0

VALEUR JENSEN MARGARET E EVP AND GENERAL COUNSEL

  • Officer
0 2011-08-31 0

VALE WYLIE W

  • Director
0 2011-05-25 0

VENROCK HEALTHCARE CAPITAL PARTNERS LP

VHCP CO-INVESTMENT HOLDINGS, LLC

HOVE ANDERS D

ROBERTS BRYAN E

VHCP MANAGEMENT, LLC

  • 10% Owner
4,784,689 2009-12-22 0

ROBERTS BRYAN E

  • 10% Owner
4,784,689 2009-12-22 0

HOVE ANDERS D

  • 10% Owner
4,784,689 2009-12-22 0

BVF PARTNERS L P/IL

BIOTECHNOLOGY VALUE FUND L P

BIOTECHNOLOGY VALUE FUND II LP

BVF INVESTMENTS LLC

BVF INC/IL

  • 10% Owner
  • INDIRECT BENEFICIAL OWNERDIRECT BENEFICIAL OWNERDIRECT BENEFICIAL OWNERDIRECT BENEFICIAL OWNERINDIRECT BENEFICIAL OWNER
5,946,547 2009-01-22 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

ROBERTS EIRY - Officer CHIEF MEDICAL OFFICER

2020-11-16 18:23:59 -0500 2020-11-12 S 2,257 $90.74 d 13,477 direct yes -5.2752 4.4251 4.4251 6 -5.2752 2

GANO KYLE - Officer CHIEF BUSINESS DEVELOPMENT OFF

2020-11-16 18:11:48 -0500 2020-11-12 S 2,257 $90.73 d 98,028 direct yes -5.2752 4.4251 4.4251 6 -5.2752 2

LIPPOLDT DARIN - Officer CHIEF LEGAL OFFICER

2020-11-16 18:20:17 -0500 2020-11-12 S 2,257 $90.72 d 30,082 direct yes -5.2752 4.4251 4.4251 6 -5.2752 2

BENEVICH ERIC - Officer CHIEF COMMERCIAL OFFICER

2020-11-16 18:27:23 -0500 2020-11-12 S 2,257 $90.71 d 17,405 direct yes -5.2752 4.4251 4.4251 6 -5.2752 2

GORMAN KEVIN CHARLES - Director - Officer CHIEF EXECUTIVE OFFICER

2020-11-16 18:16:04 -0500 2020-11-12 S 3,390 $90.78 d 441,071 direct yes -5.2752 4.4251 4.4251 6 -5.2752 2

ABERNETHY MATT - Officer CHIEF FINANCIAL OFFICER

2020-11-16 18:02:09 -0500 2020-11-12 S 2,257 $90.74 d 10,014 direct yes -5.2752 4.4251 4.4251 6 -5.2752 2

LLOYD-SMITH MALCOLM - Officer CHIEF REGULATORY OFFICER

2020-11-16 18:21:47 -0500 2020-11-12 S 2,257 $90.73 d 29,002 direct yes -5.2752 4.4251 4.4251 6 -5.2752 2

COOKE JULIE - Officer CHIEF HUMAN RESOURCES OFFICER

2020-11-16 18:10:20 -0500 2020-11-12 S 2,257 $90.73 d 11,580 direct yes -5.2752 4.4251 4.4251 6 -5.2752 2

GRIGORIADIS DIMITRI E. - Officer CHIEF RESEARCH OFFICER

2020-11-16 18:19:03 -0500 2020-11-12 S 2,257 $90.73 d 81,624 direct yes -5.2752 4.4251 4.4251 6 -5.2752 2

BOZIGIAN HAIG P. - Officer CHIEF DEVELOPMENT OFFICER

2020-11-16 18:08:41 -0500 2020-11-12 S 2,257 $90.74 d 152,694 direct yes -5.2752 4.4251 4.4251 6 -5.2752 2

BENEVICH ERIC - Officer CHIEF COMMERCIAL OFFICER

2020-11-04 18:09:09 -0500 2020-11-02 M 20,595 $35.99 a 35,969 direct -3.9673 -9.8385 2.4821 3 -12.6994 4

BENEVICH ERIC - Officer CHIEF COMMERCIAL OFFICER

2020-11-04 18:09:09 -0500 2020-11-02 M 20,595 $35.99 d 7,775 direct

BENEVICH ERIC - Officer CHIEF COMMERCIAL OFFICER

2020-11-04 18:09:09 -0500 2020-11-02 S 20,595 $96.53 d 15,374 direct yes -3.9673 -9.8385 2.4821 3 -12.6994 4

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments